Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.
about
Advances in Engineered Liver Models for Investigating Drug-Induced Liver InjuryExploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicityA model qualification method for mechanistic physiological QSP models to support model-informed drug development.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.The application of engineered liver tissues for novel drug discovery.Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics.Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.Can BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium Perspective
P2860
Q28077505-0B1473DD-13C6-4AD6-B9FC-4B5EF128CC76Q34471194-0E6970C6-6F65-4B21-BFA0-B4C395E83CD8Q35781894-8031B25D-CC45-480C-AD48-53EAF1251BECQ36600060-93622E34-9612-4C5B-A25F-2A53C93A4B6CQ36972804-DFB2BC8C-2B7B-4887-9E27-FAF7C4D92DD4Q37564187-3B71607E-5857-4F38-B393-508A1E45A095Q38374943-39F09358-03B1-40E4-8D1F-1DA7A66960CFQ38404573-6FF52E20-E53D-49EC-BFA8-B61708BADC97Q38725134-3405EADD-63DA-4BBD-BB15-4C3EEA2651FFQ38763000-8196D6BB-A5CE-4BAA-A4EB-3EFEC08D9736Q38774776-3B5DE9AA-CC56-436C-B853-275DF47B7D2FQ40376380-5B1FB67A-AC1D-4980-A161-27F0927FD3CDQ41688591-9DAFCBA5-BA79-4EA9-9BAD-279C1885FB58Q41788959-1A71E6A0-8568-460C-900C-628BEBA13DDCQ42091235-13001026-5EE1-4DE1-B850-D52C623ABB94Q43066578-C9C48726-C63A-4025-A125-56252F797C40Q57111135-98784A03-981D-4889-B406-39CC5C3DC2CF
P2860
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Linking physiology to toxicity ...... of drug-induced liver injury.
@en
type
label
Linking physiology to toxicity ...... of drug-induced liver injury.
@en
prefLabel
Linking physiology to toxicity ...... of drug-induced liver injury.
@en
P2093
P2860
P356
P1476
Linking physiology to toxicity ...... of drug-induced liver injury.
@en
P2093
Brett A Howell
Jeffrey L Woodhead
Lisl K M Shoda
Paul B Watkins
Scott Q Siler
P2860
P356
10.1002/BDD.1878
P577
2013-11-25T00:00:00Z